707 related articles for article (PubMed ID: 19447545)
1. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
2. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
3. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
4. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
6. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.
Kawakami Y; Li H; Lam JT; Krasnykh V; Curiel DT; Blackwell JL
Cancer Res; 2003 Mar; 63(6):1262-9. PubMed ID: 12649186
[TBL] [Abstract][Full Text] [Related]
7. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
8. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
9. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
10. [Anti-tumor effect of eukaryotic expressing plasmid containing soluble tumor necrotic factor-related apoptosis inducing ligand combined with human angiostatin Kringle (1 - 3) genes on human gastric cancer xenografts in nude mice].
Sun W; Jiang Z; Xiang TX; Tao XH; Huang AL; Wang PL
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):841-5. PubMed ID: 19595126
[TBL] [Abstract][Full Text] [Related]
11. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
[TBL] [Abstract][Full Text] [Related]
12. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
[TBL] [Abstract][Full Text] [Related]
13. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
[TBL] [Abstract][Full Text] [Related]
14. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
15. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
[TBL] [Abstract][Full Text] [Related]
16. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
17. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
18. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
19. [Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored].
Wang J; Gu JF; Yang SY; Xiao T; Qi R; Sun LY; Liu XY
Ai Zheng; 2006 Apr; 25(4):385-92. PubMed ID: 16613667
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL; Earel JK; Griffith TS
Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
